StemCell InstituteTSE:7096 +0.92%69 ROA % is 1.78% as of Mar. 2026, which is 50% below its 10-year median of 3.59. GuruFocus rates TSE:7096 with a GF Score™ of 69/100 and a GF Value™ of 円1,813.29 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,416 Biotechnology companies, StemCell Institute ranks better than 83.47% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. StemCell Institute's annualizedNet Income for the quarter that ended in Mar. 2026 was 円142 Mil.
StemCell Institute's average Total Assets over the quarter that ended in Mar. 2026 was 円7,989 Mil. Therefore, StemCell Institute's annualized ROA % for the quarter that ended in Mar. 2026 was 1.78%.
The historical rank and industry rank for StemCell Institute's ROA % or its related term are showing as below:
TSE:7096'
s ROA % Range Over the Past 10 Years
Min: 1.66 Med: 3.59 Max: 8.7
Current: 1.99
During the past 9 years, StemCell Institute's highest ROA % was 8.70%. The lowest was 1.66%. And the median was 3.59%.
TSE:7096's ROA % is ranked better than 83.47% of 1416
companies
in the Biotechnology industry
Industry Median: -32.87
vs TSE:7096: 1.99
StemCell Institute (TSE:7096) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Mar. 2026) net income data. The Revenue data used here is two times the semi-annual (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
StemCell Institute ROA % Related Terms
StemCell Institute ROA % Historical Data
* Premium members only.
The historical data trend for StemCell Institute's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, StemCell Institute's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
StemCell Institute ROA % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, StemCell Institute's ROA % distribution charts can be found below:
* The bar in red indicates where StemCell Institute's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
StemCell Institute (TSE:7096) has a ROA % of 1.78% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on StemCell Institute and its competitors. This is 50% below median its historical median of 3.59. Over the past decade, StemCell Institute's ROA % has ranged from 1.66 to 8.70. According to the industry distribution chart, StemCell Institute ranks #234 out of 1416 companies in the Biotechnology industry, placing it in the top 16.5%.
Is StemCell Institute's ROA % too high?
StemCell Institute's current ROA % of 1.78% is 50% below median its 10-year median of 3.59. Over the past 10 years, this metric has ranged from a low of 1.66 to a high of 8.70. Based on the distribution chart, StemCell Institute ranks #234 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, StemCell Institute has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does StemCell Institute's ROA % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, StemCell Institute ranks #234 out of 1416 companies for ROA %. This places StemCell Institute in the top 17% of its industry — outperforming the majority of peers. Historically, StemCell Institute's own ROA % has ranged from 1.66 to 8.70 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Biotechnology company?
A good ROA % depends on the Biotechnology industry context. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on StemCell Institute and its competitors. StemCell Institute's current ROA % is 1.78%, which is 50% below median its own 10-year median of 3.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is StemCell Institute stock overvalued right now?
Based on GuruFocus' analysis, StemCell Institute (TSE:7096) is currently considered Possible Value Trap. The stock's GF Value™ is 円1,813.29, compared to a current price of 円768.00 — trading 57.6% below its estimated fair value. The current ROA % is 1.78%, which is 50% below median its 10-year median of 3.59. StemCell Institute's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For StemCell Institute (TSE:7096), the current ROA % is 1.78% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is StemCell Institute (TSE:7096) Overvalued in 2026?
Based on GuruFocus' analysis, StemCell Institute stock appears to be undervalued.
The current stock price of 円768.00 is trading 57.6% below its estimated GF Value™ of 円1,813.29.
GuruFocus considers StemCell Institute to be Possible Value Trap.
Key valuation signals for TSE:7096:
ROA %: 1.78% (50% below median its 10-year median of 3.59)
GF Value™: 円1,813.29 vs. price of 円768.00 (57.6% below fair value)
No single metric tells the full story. See the TSE:7096 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
StemCell Institute is engaged in the Cell bank business that separates and stores cord blood for regenerative medicine. Cord blood is the baby's blood contained in the umbilical cord and placenta that connects the mother and baby. In its umbilical cord blood storage business, upon receiving notification from customers who have contracted, umbilical cord blood collected at obstetric facilities throughout Japan is collected, transported to the company's cell processing center within 48 hours, and it provides a service to store cells at ultra-low temperature after separating cells from blood. The Company operates in a single segment, the cell bank business sales consist of three components: technical fees, storage fees, and other fees.
69GF Score
Get the complete analysis for TSE:7096
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7096 has been successfully added to your 
